ArticleJournal of advanced research2026
Endoplasmic reticulum stress exacerbates ischemia-reperfusion-induced pulmonary endothelial barrier dysfunction by activating TXNDC5.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mitochondrial-endoplasmic reticulum interactions in lung diseases.Cell death & disease · 2026Review
- NF-Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLung ischemia-reperfusion injury (LIRI)-a fatal complication following major surgery, trauma, or shock- is characterized by pulmonary endothelial barrier (PEB) dysfunction. Although thioredoxin domain-containing protein 5 (TXNDC5) regulates endothelial homeostasis, its role in LIRI pathogenesis remains unknown.
objectivesIn the present study, we investigate the role of TXNDC5 in LIRI-induced PEB disruption and explore its underlying mechanisms and therapeutic potential.
methodsWe established LIRI models in rats (left pulmonary hilum occlusion) and human umbilical vein endothelial cells (oxygen-glucose deprivation/reperfusion). TXNDC5 expression was modulated via AAV-shRNA knockdown, whereas endoplasmic reticulum (ER) stress was inhibited pharmacologically (4-PBA and Ceapin-A7). Structural and functional changes of the PEB, including HSP90/eNOS complex stability, were examined. Mechanistic studies included ChIP-seq identified ATF6 binding to the TXNDC5 promoter, followed by rescue experiments with ATF6 inhibition and TXNDC5 overexpression. Clinical validation was performed using plasma proteomics in patients with LIRI. A TXNDC5-based nomogram model for LIRI early-warning was constructed and internally validated. Incremental prediction value of TXNDC5 was evaluated using net reclassification improvement (NRI) and integrated discrimination improvement (IDI).
resultsSingle-cell RNA sequencing revealed TXNDC5 upregulation in pulmonary endothelial cells during LIRI, correlating with PEB disruption, apoptosis, ER stress, and NF-κB activation. TXNDC5 knockdown restored HSP90/eNOS stability and improved endothelial integrity in vitro/vivo. Ceapin-A7, or 4-PBA, attenuated TXNDC5-driven PEB injury, and TXNDC5 overexpression confirmed the causal role of the ATF6-TXNDC5 axis. Mechanistically, ER stress promoted TXNDC5 transcription via ATF6 binding to its promoter. Clinically, elevated plasma TXNDC5 levels predicted LIRI and correlated with the severity of the condition. Incorporating the TXNDC5 index into the clinical predictors model enhanced the forecast of LIRI, as demonstrated by the NRI and IDI.
conclusionOur findings demonstrate that ER stress-induced TXNDC5 upregulation exacerbates LIRI by impairing HSP90/eNOS-dependent endothelial function. ER stress-TXNDC5 signaling is a mechanistically distinct and potential target in LIRI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.